Sarepta Therapeutic (SRPT) Label More Inclusive Than Anticipated - Oppenheimer
Oppenheimer analyst Michelle Gilson reiterated an Outperform rating and $60 price target on Sarepta Therapeutic (NASDAQ: SRPT) after the FDA announced the approval of eteplirsen (EXONDYS51) for the treatment of DMD amenable to Exon 51 skipping.
In conjunction with eteplirsen's accelerated approval, Sarepta will receive a pediatric review voucher that could be worth up to $350M.
"Notably, the label includes all patients with DMD amenable to exon 51 skipping, and does not restrict use by ambulatory status nor age," the analyst notes.
For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.
Shares of Sarepta Therapeutic closed at $28.15 yesterday.